Takashi Fukuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takashi Fukuda has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Takahashi
Yamashita Thyroid Hospital
8 shared publications - Hiroyuki Yamashita
Department of Surgery, Yamashita Thyroid Hospital , Fukuoka 812-0034
8 shared publications - Hisakazu Shindo
Department of Surgery, Yamashita Thyroid Hospital , Fukuoka 812-0034
8 shared publications - Seigo Tachibana
Yamashita Thyroid Hospital
8 shared publications - Shinya Sato
Department of Surgery, Yamashita Thyroid Hospital , Fukuoka 812-0034
8 shared publications - Yuji Nagayama
Yamashita Thyroid Hospital
8 shared publications
Latest Publications
- 9 July 2026
- Published by Taylor & Francis in Endocrine Research
- Vol. 51  (4) , 193-202
Impact of antithyroid drug duration on radioactive iodine therapy efficacy in Graves’ disease in Japan: a propensity score-matched analysis using thyroid weight-based outcomes
Radioactive iodine therapy (RAIT) is an established treatment option for Graves’ disease (GD). In Japan, antithyroid drugs (ATDs) are typically first-line therapy, with RAIT or thyroidectomy reserv...
- 9 July 2026
- Published by Taylor & Francis in Endocrine Research
- Vol. 51  (4) , 193-202
Impact of antithyroid drug duration on radioactive iodine therapy efficacy in Graves’ disease in Japan: a propensity score-matched analysis using thyroid weight-based outcomes
Radioactive iodine therapy (RAIT) is an established treatment option for Graves’ disease (GD). In Japan, antithyroid drugs (ATDs) are typically first-line therapy, with RAIT or thyroidectomy reserv...
- 17 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111  (12) , 3525-3534
Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine
Context: Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action. Objective: The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients. Methods: This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups. Results: In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3. Conclusion: In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.
- 17 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111  (12) , 3525-3534
Serum free triiodothyronine as an adjunctive marker for thyroid hormone status in athyreotic patients on levothyroxine
Context: Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action. Objective: The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients. Methods: This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups. Results: In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3. Conclusion: In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73  (7) , 883-887
Multiple thyroid cysts: a benign and stable clinical entity based on longitudinal data
Multiple thyroid cysts are commonly detected by ultrasonography, and are considered clinically insignificant. On the other hand, polycystic thyroid disease (PCTD) has been proposed as a cause of antibody-negative hypothyroidism in iodine-replete regions; however, the clinical characteristics and natural history of multiple thyroid cysts as a broader entity remain unclear. To elucidate these issues, we retrospectively reviewed 7,727 consecutive new outpatients at a high-volume thyroid center between 2013 and 2016. Multiple thyroid cysts were defined as ≥4 cysts (≥3 mm in diameter) in the absence of thyroid autoantibodies. Among all patients, 164 (2.1%) met the criteria. The mean age was 58.3 years, and 91.0% were female. At presentation, 86.6% were euthyroid, 6.1% and 6.7% had subclinical hypothyroidism and subclinical hyperthyroidism, respectively, and one patient had Graves’ disease. Thus, approximately 6% of multiple thyroid cysts may be PCTD. Forty-six patients were followed up for ≥5 years (mean 9.8 years) without iodine restriction. Thyroid function remained stable in most cases, with no significant progression to overt dysfunction and no requirement for surgical or interventional treatment. Ultrasonographic findings ranged from numerous diffuse cysts throughout the gland to several scattered or localized cysts. Some cysts remained stable, some increased, and others decreased in size in the follow-up periods. The cyst distribution patterns (diffuse versus localized) were not associated with thyroid function. Therefore, multiple thyroid cysts may generally represent benign and stable clinical entities, supporting conservative management with periodic monitoring in most patients.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73  (7) , 883-887
Open AccessMultiple thyroid cysts: a benign and stable clinical entity based on longitudinal data
Multiple thyroid cysts are commonly detected by ultrasonography, and are considered clinically insignificant. On the other hand, polycystic thyroid disease (PCTD) has been proposed as a cause of antibody-negative hypothyroidism in iodine-replete regions; however, the clinical characteristics and natural history of multiple thyroid cysts as a broader entity remain unclear. To elucidate these issues, we retrospectively reviewed 7,727 consecutive new outpatients at a high-volume thyroid center between 2013 and 2016. Multiple thyroid cysts were defined as ≥4 cysts (≥3 mm in diameter) in the absence of thyroid autoantibodies. Among all patients, 164 (2.1%) met the criteria. The mean age was 58.3 years, and 91.0% were female. At presentation, 86.6% were euthyroid, 6.1% and 6.7% had subclinical hypothyroidism and subclinical hyperthyroidism, respectively, and one patient had Graves’ disease. Thus, approximately 6% of multiple thyroid cysts may be PCTD. Forty-six patients were followed up for ≥5 years (mean 9.8 years) without iodine restriction. Thyroid function remained stable in most cases, with no significant progression to overt dysfunction and no requirement for surgical or interventional treatment. Ultrasonographic findings ranged from numerous diffuse cysts throughout the gland to several scattered or localized cysts. Some cysts remained stable, some increased, and others decreased in size in the follow-up periods. The cyst distribution patterns (diffuse versus localized) were not associated with thyroid function. Therefore, multiple thyroid cysts may generally represent benign and stable clinical entities, supporting conservative management with periodic monitoring in most patients.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73  (7) , 837-846
Early predictors of 6-month thyroid-stimulating antibody levels after radioactive iodine therapy for Graves’ disease: implications for pregnancy planning
Current guidelines recommend a 6-month contraception period following radioactive iodine therapy (RAIT) for Graves’ disease (GD), based primarily on radiation safety considerations; however, they do not account for the post-treatment surge in thyroid-stimulating antibodies (TSAb), which poses risks for fetal and neonatal GD. This retrospective study aimed to identify factors influencing TSAb trajectories and construct a predictive model for TSAb levels at 6 months after RAIT. We analyzed 82 patients who underwent RAIT, with TSAb values standardized to the upper limit of normal (ULN) to account for different assay methods. Multivariable linear regression identified the duration of antithyroid drug and potassium iodide administration, pre-RAIT TSAb levels, changes in TSAb at 3 months (3M), fractional reduction in TW at 3M, and assay method as significant predictors of TSAb levels at 6 months (adjusted R2 = 0.87). A prediction score derived from this model demonstrated excellent diagnostic performance. Receiver operating characteristic analysis yielded an area under the curve of 0.99 for predicting TSAb >3.3 ULN, corresponding to the threshold for fetal GD monitoring at approximately 20 weeks of gestation, and 0.94 for TSAb >1.0 ULN. The prediction score significantly outperformed single predictors, including baseline TSAb levels and early post-TSAb changes. In conclusion, we developed a highly accurate predictive model for TSAb levels at 6 months after RAIT by integrating early post-treatment data with pre-RAIT clinical parameters. This model enables identification of patients at risk of persistent TSAb elevation, supporting individualized counseling regarding pregnancy planning beyond the conventional 6-month contraception period.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73  (7) , 837-846
Open AccessEarly predictors of 6-month thyroid-stimulating antibody levels after radioactive iodine therapy for Graves’ disease: implications for pregnancy planning
Current guidelines recommend a 6-month contraception period following radioactive iodine therapy (RAIT) for Graves’ disease (GD), based primarily on radiation safety considerations; however, they do not account for the post-treatment surge in thyroid-stimulating antibodies (TSAb), which poses risks for fetal and neonatal GD. This retrospective study aimed to identify factors influencing TSAb trajectories and construct a predictive model for TSAb levels at 6 months after RAIT. We analyzed 82 patients who underwent RAIT, with TSAb values standardized to the upper limit of normal (ULN) to account for different assay methods. Multivariable linear regression identified the duration of antithyroid drug and potassium iodide administration, pre-RAIT TSAb levels, changes in TSAb at 3 months (3M), fractional reduction in TW at 3M, and assay method as significant predictors of TSAb levels at 6 months (adjusted R2 = 0.87). A prediction score derived from this model demonstrated excellent diagnostic performance. Receiver operating characteristic analysis yielded an area under the curve of 0.99 for predicting TSAb >3.3 ULN, corresponding to the threshold for fetal GD monitoring at approximately 20 weeks of gestation, and 0.94 for TSAb >1.0 ULN. The prediction score significantly outperformed single predictors, including baseline TSAb levels and early post-TSAb changes. In conclusion, we developed a highly accurate predictive model for TSAb levels at 6 months after RAIT by integrating early post-treatment data with pre-RAIT clinical parameters. This model enables identification of patients at risk of persistent TSAb elevation, supporting individualized counseling regarding pregnancy planning beyond the conventional 6-month contraception period.
- 11 September 2025
- Published by Taylor & Francis in Endocrine Research
- Vol. 50  (4) , 271-278
Development of painless thyroiditis after thyroid lobectomy in patients with Hashimoto’s thyroiditis
Postoperative hypothyroidism, a complication of thyroid lobectomy, occurs frequently. Unique cases of post-lobectomy painless thyroiditis, a pathology not previously reported, were recently observed in our practice. In this study, we aimed to retrospectively investigate the frequency and characteristics of thyroid dysfunction after lobectomy, focusing on painless thyroiditis. A total of 193 patients with thyroid tumors, including 66 with Hashimoto's thyroiditis and 127 without Hashimoto's thyroiditis, underwent thyroid lobectomy. These patients were followed up for 49.6 (12-118) months. Thyroid dysfunction occurred in 20.7% of patients, including 31.8% (21/66) and 14.9% (19/127) of those with and without Hashimoto's thyroiditis, respectively. The types of thyroid dysfunction included thyrotoxicosis (10.0%), subclinical hypothyroidism (47.5%), and overt hypothyroidism (42.5%). Nine of 21 patients with Hashimoto's thyroiditis who developed thyroid dysfunction 1-4 months after lobectomy were diagnosed with painless thyroiditis, based on the characteristic transient hypoechogenic pattern on ultrasonography during hormonal fluctuations. Four patients developed thyrotoxicosis, one of whom subsequently become hypothyroid. Thyroid function returned to normal in all four patients. Two patients tested negative for TSH receptor antibody during the thyrotoxic period. The remaining five patients developed hypothyroidism, which was transient in three patients. Painless thyroiditis develops as post-lobectomy thyroid dysfunction in patients with Hashimoto's thyroiditis. We propose naming this condition "post-lobectomy thyroiditis," as it is believed to be triggered by surgical manipulation of the thyroid gland in individuals with underlying subclinical thyroid autoimmunity. Given its transient nature in most cases, distinguishing this condition from postoperative permanent hypothyroidism is essential.
- 11 September 2025
- Published by Taylor & Francis in Endocrine Research
- Vol. 50  (4) , 271-278
Development of painless thyroiditis after thyroid lobectomy in patients with Hashimoto’s thyroiditis
Postoperative hypothyroidism, a complication of thyroid lobectomy, occurs frequently. Unique cases of post-lobectomy painless thyroiditis, a pathology not previously reported, were recently observed in our practice. In this study, we aimed to retrospectively investigate the frequency and characteristics of thyroid dysfunction after lobectomy, focusing on painless thyroiditis. A total of 193 patients with thyroid tumors, including 66 with Hashimoto's thyroiditis and 127 without Hashimoto's thyroiditis, underwent thyroid lobectomy. These patients were followed up for 49.6 (12-118) months. Thyroid dysfunction occurred in 20.7% of patients, including 31.8% (21/66) and 14.9% (19/127) of those with and without Hashimoto's thyroiditis, respectively. The types of thyroid dysfunction included thyrotoxicosis (10.0%), subclinical hypothyroidism (47.5%), and overt hypothyroidism (42.5%). Nine of 21 patients with Hashimoto's thyroiditis who developed thyroid dysfunction 1-4 months after lobectomy were diagnosed with painless thyroiditis, based on the characteristic transient hypoechogenic pattern on ultrasonography during hormonal fluctuations. Four patients developed thyrotoxicosis, one of whom subsequently become hypothyroid. Thyroid function returned to normal in all four patients. Two patients tested negative for TSH receptor antibody during the thyrotoxic period. The remaining five patients developed hypothyroidism, which was transient in three patients. Painless thyroiditis develops as post-lobectomy thyroid dysfunction in patients with Hashimoto's thyroiditis. We propose naming this condition "post-lobectomy thyroiditis," as it is believed to be triggered by surgical manipulation of the thyroid gland in individuals with underlying subclinical thyroid autoimmunity. Given its transient nature in most cases, distinguishing this condition from postoperative permanent hypothyroidism is essential.
- 2 June 2025
- Published by Taylor & Francis in Endocrine Research
- p. 1-6
Acute Transient Thyroid Cracking: A Proposal of a New Disease Entity as a Mild Form of Acute Transient Thyroid Swelling
Objective: This study aims to investigate the clinical and ultrasonographic features of thyroid swelling following fine-needle aspiration biopsy (FNAB), and to distinguish between symptomatic and asymptomatic forms.Methods: We retrospectively reviewed 872 patients who underwent thyroid ultrasonography before and after FNAB between January and November 2024. Patients showing new hypoechoic cracking after FNAB were identified. Clinical symptoms, degree of thyroid swelling, and outcomes were evaluated.Results: Hypoechoic cracking developed in 18 patients (2.1%), appearing immediately in 17 and at 4 hours in one. Three patients (17%) experienced symptoms such as pain or compression, all with thyroid swelling exceeding 1.8-fold the original size. The remaining 15 patients were asymptomatic, with swelling less than 1.5-fold. No clinical characteristics were significantly associated with the development of symptoms. All patients recovered spontaneously; two symptomatic cases received steroid treatment.Conclusion: Post-FNAB thyroid swelling can be classified into two entities: typical, symptomatic acute transient thyroid swelling (ATTS) and a newly proposed asymptomatic form, acute transient thyroid cracking (ATTC). Recognizing ATTC as a mild, self-limiting condition is important for avoiding unnecessary treatment and alleviating patient concern.
- 2 June 2025
- Published by Taylor & Francis in Endocrine Research
- p. 1-6
Acute Transient Thyroid Cracking: A Proposal of a New Disease Entity as a Mild Form of Acute Transient Thyroid Swelling
Objective: This study aims to investigate the clinical and ultrasonographic features of thyroid swelling following fine-needle aspiration biopsy (FNAB), and to distinguish between symptomatic and asymptomatic forms.Methods: We retrospectively reviewed 872 patients who underwent thyroid ultrasonography before and after FNAB between January and November 2024. Patients showing new hypoechoic cracking after FNAB were identified. Clinical symptoms, degree of thyroid swelling, and outcomes were evaluated.Results: Hypoechoic cracking developed in 18 patients (2.1%), appearing immediately in 17 and at 4 hours in one. Three patients (17%) experienced symptoms such as pain or compression, all with thyroid swelling exceeding 1.8-fold the original size. The remaining 15 patients were asymptomatic, with swelling less than 1.5-fold. No clinical characteristics were significantly associated with the development of symptoms. All patients recovered spontaneously; two symptomatic cases received steroid treatment.Conclusion: Post-FNAB thyroid swelling can be classified into two entities: typical, symptomatic acute transient thyroid swelling (ATTS) and a newly proposed asymptomatic form, acute transient thyroid cracking (ATTC). Recognizing ATTC as a mild, self-limiting condition is important for avoiding unnecessary treatment and alleviating patient concern.
- Open Access
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11  (1) , cr.25-0465
Paradoxical Elevation of Parathyroid Hormone Levels following Preoperative Native Vitamin D Supplementation in a Patient with Graves’ Disease Undergoing Total Thyroidectomy: A Case Report
INTRODUCTION: Hypocalcemia is a common complication after total thyroidectomy, particularly in patients with Graves’ disease and high bone turnover. Preoperative vitamin D deficiency is a known risk factor for postoperative hypocalcemia; however, the effects of vitamin D supplementation remain controversial. This is the first study to document a paradoxical increase in parathyroid hormone (PTH) levels after preoperative vitamin D supplementation in a patient undergoing total thyroidectomy.CASE PRESENTATION: We report the case of a 68-year-old woman with Graves’ disease and coexisting thyroid cancer who received native vitamin D (2000 IU/day) for 4 weeks before surgery. This unexpectedly resulted in a marked increase in PTH levels and bone formation markers, suggesting the worsening of secondary hyperparathyroidism. Interestingly, fibroblast growth factor 23 levels remained unchanged despite an increase in PTH and 1,25-dihydroxyvitamin D levels. Postoperatively, she developed transient hypoparathyroidism.CONCLUSIONS: Native vitamin D supplementation may, paradoxically, worsen secondary hyperparathyroidism in some patients, highlighting the need for careful preoperative metabolic assessment and individualized management strategies.
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11  (1) , cr.25-0465
Open AccessParadoxical Elevation of Parathyroid Hormone Levels following Preoperative Native Vitamin D Supplementation in a Patient with Graves’ Disease Undergoing Total Thyroidectomy: A Case Report
INTRODUCTION: Hypocalcemia is a common complication after total thyroidectomy, particularly in patients with Graves’ disease and high bone turnover. Preoperative vitamin D deficiency is a known risk factor for postoperative hypocalcemia; however, the effects of vitamin D supplementation remain controversial. This is the first study to document a paradoxical increase in parathyroid hormone (PTH) levels after preoperative vitamin D supplementation in a patient undergoing total thyroidectomy.CASE PRESENTATION: We report the case of a 68-year-old woman with Graves’ disease and coexisting thyroid cancer who received native vitamin D (2000 IU/day) for 4 weeks before surgery. This unexpectedly resulted in a marked increase in PTH levels and bone formation markers, suggesting the worsening of secondary hyperparathyroidism. Interestingly, fibroblast growth factor 23 levels remained unchanged despite an increase in PTH and 1,25-dihydroxyvitamin D levels. Postoperatively, she developed transient hypoparathyroidism.CONCLUSIONS: Native vitamin D supplementation may, paradoxically, worsen secondary hyperparathyroidism in some patients, highlighting the need for careful preoperative metabolic assessment and individualized management strategies.
- Open Access
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72  (7) , 813-818
Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves’ disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves’ disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves’ disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72  (7) , 813-818
Open AccessEarly postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves’ disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves’ disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves’ disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.